Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanggan Liyan Pill is a Traditional Chinese Medicine (TCM) candidate developed by Xi'an Xintong Pharmaceutical Research Co., Ltd. for the treatment of acute pharyngitis. Formulated based on TCM principles to address "wind-heat" syndrome, the medication is designed to clear heat, resolve toxins, and alleviate pharyngeal swelling and pain. It has undergone Phase 3 clinical evaluation in China, where it was assessed for its ability to reduce clinical symptoms such as sore throat, congestion, and fever associated with upper respiratory tract inflammation. As a TCM product, it utilizes a multi-component approach to modulate inflammatory responses and provide symptomatic relief in patients with acute pharyngeal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kanggan Liyan Pill.